Breaking Down Anupam Rasayan India Limited Financial Health: Key Insights for Investors

Curious whether Anupam Rasayan's recent performance merits investor attention? In Q2 FY26 the company reported total revenue of ₹7,392 million, a sharp 149% jump versus Q2 FY25, lifting H1 FY26 consolidated revenue to ₹1,217 crore (up 122% YoY) while management is guiding a 30-35% revenue rise for FY26 supported by a healthy order book of ₹14,646 crore; on profitability, Q2 FY26 EBITDA was ₹1,436 million (margin 19%) and PAT was ₹572 million (7.8%), versus prior-period margins and Q4 FY25 EBITDA of ₹1,500 million (30% margin) and net profit of ₹44.57 crore; leverage and liquidity show a net debt-to-EBITDA of 2.89, completed capex of ₹650 crore out of ₹670 crore planned, and a material improvement in working capital days from 409 in FY25 to 247 in H1 FY26-read on for a detailed breakdown of revenue drivers, margin dynamics, debt structure, valuation cues, risks and growth levers.

Anupam Rasayan India Limited (ANURAS.NS) - Revenue Analysis

Anupam Rasayan delivered exceptionally strong top-line momentum across recent periods, driven by diversified demand from pharmaceuticals, polymers and a recovering agrochemical segment.

• Q2 FY26 total revenue: ₹7,392 million (up 149% YoY from ₹2,959 million in Q2 FY25).
• Consolidated revenue for H1 FY26: ₹1,217 crore, up 122% YoY.
• Q4 FY25 revenue: ₹5,057 million, up 22% from ₹4,130 million in Q4 FY24.
• Agrochemicals contributed 49% of total revenue for the nine months ended December 2024.
• Company guidance: expects 30-35% revenue growth in FY26, supported by ongoing commercializations.
• Order book: ~₹14,646 crore, with a significant portion expected to be commercialized in FY26.

• Primary growth drivers: increasing demand in specialty chemicals for pharmaceuticals and polymers, recovery in agrochemicals, and ramp-up of new commercial contracts from the order book.
• Near-term outlook: management guidance of 30-35% revenue growth for FY26 predicated on timely execution and commercialization of scheduled projects.

Further context on investor interest and ownership trends can be found here: Exploring Anupam Rasayan India Limited Investor Profile: Who's Buying and Why?

Anupam Rasayan India Limited (ANURAS.NS) - Profitability Metrics

Key profitability figures across recent quarters demonstrate a mix of strong absolute growth in earnings and divergent margin trends.

• EBITDA for Q2 FY26: ₹1,436 million (up 74% YoY from ₹824 million in Q2 FY25).
• EBITDA margin Q2 FY26: 19% (versus 28% in Q2 FY25).
• EBITDA for Q4 FY25: ₹1,500 million (up 43% YoY from ₹1,047 million in Q4 FY24); margin 30%.
• PAT for Q2 FY26: ₹572 million (up 87% YoY from ₹306 million in Q2 FY25); PAT margin 7.8% (versus 10.3% in Q2 FY25).
• Net profit Q4 FY25: ₹44.57 crore (₹445.7 million), up 44.19% from ₹30.91 crore in Q4 FY24.

• Large YoY growth in EBITDA and PAT highlights revenue or volume strength; shrinking EBITDA and PAT margins in Q2 FY26 versus Q2 FY25 point to rising costs, mix shift, or one-off items despite higher absolute profits.
• Q4 FY25's higher margin (30%) versus Q2 FY26 (19%) suggests seasonal or non-recurring factors elevated profitability in that quarter.
• Investors should cross-check revenue growth, input-cost trends, and exceptional items when interpreting margin compression amid rising absolute earnings.

Further context on company background and business model: Anupam Rasayan India Limited: History, Ownership, Mission, How It Works & Makes Money

Anupam Rasayan India Limited (ANURAS.NS) - Debt vs. Equity Structure

• Net debt-to-EBITDA: 2.89 - a moderate leverage level indicating obligation coverage by operating earnings is adequate but requires monitoring as growth investments ramp up.
• CapEx execution: ₹650 crore completed out of a planned ₹670 crore, signaling near-complete capacity investments with only ₹20 crore remaining.
• Order book strength: approximately ₹14,646 crore, with a material portion slated for commercialization in FY26, supporting future revenue visibility.
• Working capital focus: management has been actively reducing the working capital cycle after earlier upswing this year and continues close monitoring to ensure efficient capital utilisation.
• Investment approach: capital allocation remains aligned with strategic growth and risk control - each rupee deployed is evaluated for strategic fit and downside protection.

• Implication for equity holders: moderate leverage supports growth but necessitates continued working capital discipline to protect margins and cash generation.
• Liquidity & execution: near-complete capex reduces execution risk; strong order book provides medium-term revenue visibility that can improve leverage ratios if commercialized as planned.
• Risk controls: management's emphasis on scrutinised capital deployment and working capital optimisation is central to maintaining a balanced debt vs. equity posture.

Anupam Rasayan India Limited (ANURAS.NS) - Liquidity and Solvency

• Working capital days reduced from 409 days in FY25 to 247 days in H1 FY26, reflecting faster receivable collections and inventory turns.
• Capital expenditure largely completed: ₹650 crore out of a planned ₹670 crore, supporting near-term capacity and commercialization plans.
• Robust order book of approximately ₹14,646 crore, with a significant portion targeted for commercialization in FY26.
• Continued close monitoring of working capital to enhance capital efficiency and liquidity.
• Investment strategy aligned to strategic growth and risk control - deploying capital where it supports long-term margins and cash generation.

Anupam Rasayan India Limited (ANURAS.NS) - Valuation Analysis

• Net debt-to-EBITDA ratio: 2.89 - indicates a moderate leverage level relative to current earnings.
• Working capital cycle: deliberate focus on reduction to boost liquidity and improve cash conversion.
• Capital expenditure: ₹650 crore completed out of a planned ₹670 crore, signaling near-completion of the current capex program.
• Order book: approximately ₹14,646 crore, with a substantial portion expected to be commercialized in FY26 - providing multi-year revenue visibility.
• Investment approach: capital deployment is being prioritized to align with strategic growth while controlling risk and ensuring returns.

• Short-term catalysts: commercialization ramp in FY26, working-capital improvements translating to higher free cash flow.
• Key risks to valuation: slower-than-expected commercialization, margin pressure during scale-up, and any step-up in leverage if incremental capex or working-capital needs persist.
• Valuation watchpoints for investors: EBITDA trajectory post-FY26 commercialization, actual capex-to-outcome payback, and net-debt trends versus EBITDA expansion.

Anupam Rasayan India Limited (ANURAS.NS) - Risk Factors

• Regulatory & environmental risk: The specialty chemicals and agrochemical intermediates business faces tightening environmental regulations (emission controls, waste-water treatment, hazardous chemical handling) that can require capex and increase ongoing compliance costs. Historically, companies in this sector have faced single-event compliance capex ranging from INR 20-150 crore depending on scale.
• Raw material price volatility: Feedstock and intermediates (basic petrochemical derivatives, solvents, chlorine/caustic-related inputs) account for a large share of cost of goods sold. A sustained 10-20% move in key raw material prices can compress gross margins materially-typical sensitivity in specialty chemical manufacturers is a 200-800 bps margin swing for each ~10% input cost change.
• Agrochemical demand seasonality: The company's agrochemical segment revenue is skewed to sowing/harvest cycles; reported quarterly revenue can fluctuate 20-40% year-on-year between peak and off-peak quarters in agriculture-driven geographies.
• Foreign exchange exposure: With substantial exports (industry peers commonly export 40-70% of production), variations in INR vs. USD/EUR affect both top-line and imported feedstock costs. A 5-10% INR appreciation/depreciation can alter reported EBITDA by several percentage points depending on natural hedges.
• Competitive landscape: ANURAS.NS competes with large domestic players and global specialty chemical suppliers-pricing pressure and customer consolidation can reduce bargaining power and elongate receivable cycles.
• Operational risks: Supply-chain disruptions (raw-material shortages, logistics constraints), plant shutdowns, and process safety incidents pose risks to continuous production. Single-site concentration for some intermediates increases vulnerability to disruptions.

• Mitigants and monitoring points for investors: assess the company's capex plan for environmental compliance, trend in gross/EBITDA margins (quarterly), hedging policy for forex, raw material procurement contracts, diversification of end-markets (agro vs. pharma/industrial intermediates), and the geographic distribution of manufacturing sites.
• Key red flags to watch: material deterioration in working capital metrics (inventory or receivable days rising >20% Y/Y), margin contraction >300 bps without corresponding volume benefit, sharp increase in leverage, or repeated regulatory notices/closures.

Anupam Rasayan India Limited (ANURAS.NS) - Growth Opportunities

• FY26 revenue growth guidance: 30-35% year‑on‑year.
• Order book: ~₹14,646 crore, with a substantial portion slated for commercialization in FY26.
• Capex execution: ₹650 crore completed out of planned ₹670 crore (≈97% complete).
• Working capital focus: active reductions in the working capital cycle to improve liquidity and capital turnover.

• Demand mix: continued strength in specialty chemicals for pharmaceuticals and polymers; expectation of agrochemical recovery contributing incremental volumes in FY26.
• Order‑to‑revenue conversion: commercialization pipeline from the ₹14,646 crore order book expected to drive material FY26 revenue recognition.
• Capital deployment: near‑complete capex program limits incremental cash outflows while expanding commercial capacity.
• Capital efficiency: deliberate working capital reduction efforts to free cash and support faster deleveraging or re‑investment.